EGFR and neoplasm: Given the observations of possible suppression of the anti-tumour immune response in mice null for miR-21 [52], targeted delivery to the tumour may be required, for example, by coupling a miR-21 antisense sequence to an EGFR aptamer, as described by Shu and colleagues [65].